source
- Biotech firm Biogen secures Chinese approval for felzartamab in second-line multiple myelomaBiogen announced that its monoclonal antibody felzartamab has received regulatory clearance in China for use in patients with multiple myeloma who have already received first-line therapy. The app…
- FDA grants accelerated approval to Bristol Myers' Zenbexus, first CELMoD for multiple myelomaThe FDA issued an accelerated approval on Thursday for Zenbexus, a multiple myeloma therapy that Bristol Myers Squibb inherited from its Celgene acquisition. Zenbexus belongs to a new class of pro…